Auto-generated from public data. Not the firm's stated position.
Eclosion SA appears to focus on early-stage healthtech investments, particularly in specialized therapeutic areas including fibrosis, reproductive health, and neurological treatments. Based on disclosed data, the firm deploys check sizes between €0.1M and €1.5M at pre-seed and seed stages, suggesting a strategy targeting European biotech and medtech ventures in their formative phases.
Generated 16 Oct 2026 from disclosed sectors, stages, and portfolio companies. Firms can update this by emailing [email protected].
Focus and check size from the firm's website. Website reachable as of Sept 2026.
A fit check scores your pitch against their thesis, stage and ticket. An email draft uses their real deals and thesis, not a template.